pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Sep 3·1 min read
save

Gene-edited pig kidneys enable patients to go months without dialysis before receiving human transplants

Sep 3, 2026·read at STAT ↗Positive

Doctors at eGenesis reported that two patients who received genetically engineered pig kidneys were later able to receive human donor kidneys after a period on dialysis. The transition was not seamless; each patient had the xenograft removed and returned to dialysis for several months before a human organ became available.

The ability to spend a substantial time off dialysis demonstrates a milestone for xenograft research, confirming earlier primate studies that suggested the pig kidneys would not provoke problematic antibodies.

The cases mark the first successful handoff from a pig kidney to a human kidney in clinical settings, highlighting progress in interspecies transplant technology.

eGenesis is among a small group of biotech firms pursuing xenografts, and the outcomes may influence future development of pig organ transplants for patients with kidney failure.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Recipients of gene-edited pig kidneys successfully receive human organs”

read at STAT ↗
500 words · retrieved Sep 3
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Ultragenyx Pharmaceutical Inc.
topics
Nephrology3Approval2CardiologyNeurologyRare Disease

related stories

  • 16h agoCaribou layoffs could wipe out 90% of staffBioSpace
  • Sep 23Roche-Ionis’ RNA therapy reduces kidney disease marker, opening path to swift FDA nodBioSpace
  • Sep 23Ionis-Otsuka offer 'groundbreaking' improvement in function and survival for genetic type of ALSBioSpace
  • Sep 222026 IPO blitz continues with 4 new biotech filingsBioSpace
  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive